Collaboration aims to identify biological signatures and patient subpopulations most likely to benefit from BioAegis’ recombinant human plasma gelsolin (rhu-pGSN), a novel immune modulator for inflammatory diseases.
NORTH BRUNSWICK, N.J., April 21, 2026 (GLOBE NEWSWIRE) — BioAegis Therapeutics, a pioneering clinical-stage biotech company developing innovative therapies for inflammatory diseases, announces a strategic collaboration with Prenosis®, a leader in biology-driven artificial intelligence solutions for precision medicine, to evaluate biomarkers and patient subpopulations that may demonstrate enhanced response to BioAegis’ gelsolin therapy.
BioAegis’ portfolio is built around plasma gelsolin, a highly conserved and critical immune regulatory protein which rebalances dysfunctional inflammation without suppressing immune function.
Under the collaboration, Prenosis will apply its precision medicine platform to analyze biospecimens and clinical data from BioAegis’ ongoing 600-patient Phase 2 clinical trial, BTI-203, which is evaluating recombinant human plasma gelsolin (rhu-pGSN) for the treatment of moderate-to-severe acute respiratory distress syndrome (ARDS) (NCT05947955), a life-threatening condition characterized by severe lung inflammation and respiratory failure. The goal of the collaboration is to identify biological signatures and patient subgroups that may preferentially benefit from gelsolin therapy, further advancing a precision medicine approach to critical care.
ORIGINALLY PUBLISHED BY BIOAEGIS. READ THE FULL RELEASE >